These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 8289526)

  • 21. [Monoclonal antibodies in the treatment of septic shock].
    Trilla A; Alonso P
    Med Clin (Barc); 1992 Dec; 99(20):778-80. PubMed ID: 1460950
    [No Abstract]   [Full Text] [Related]  

  • 22. [Treatment with monoclonal anti-endotoxin antibodies of patients with sepsis caused by Gram-negative bacteria].
    Ned Tijdschr Geneeskd; 1991 Jul; 135(28):1289-91. PubMed ID: 1861770
    [No Abstract]   [Full Text] [Related]  

  • 23. Cost-effectiveness of HA-1A monoclonal antibody for gram-negative sepsis. Economic assessment of a new therapeutic agent.
    Schulman KA; Glick HA; Rubin H; Eisenberg JM
    JAMA; 1991 Dec; 266(24):3466-71. PubMed ID: 1744962
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Anti-endotoxin monoclonal antibodies in the treatment of gram-negative germ sepsis].
    Baumgartner JD
    Rev Prat; 1991 Jun; 41(16):1479-82. PubMed ID: 1853112
    [No Abstract]   [Full Text] [Related]  

  • 25. Anti-endotoxin monoclonal antibodies.
    Ziegler EJ; Smith CR
    N Engl J Med; 1992 Apr; 326(17):1165. PubMed ID: 1552929
    [No Abstract]   [Full Text] [Related]  

  • 26. Anti-endotoxin monoclonal antibodies.
    Warren HS; Danner RL; Munford RS
    N Engl J Med; 1992 Apr; 326(17):1153-7. PubMed ID: 1552919
    [No Abstract]   [Full Text] [Related]  

  • 27. Anti-endotoxin monoclonal antibodies--a second look.
    Wenzel RP
    N Engl J Med; 1992 Apr; 326(17):1151-3. PubMed ID: 1552918
    [No Abstract]   [Full Text] [Related]  

  • 28. Cost-effectiveness of HA-1A treatment for patients with sepsis.
    van Hout BA; Birnie E; Redekop WK; Lorijn RH; Bossuyt PM; Rutten FF
    Prog Clin Biol Res; 1994; 388():435-43. PubMed ID: 7831376
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Life-saving immunotherapy with cross-reactive monoclonal antibodies against endotoxin: a critical evaluation of experimental and clinical studies.
    Cornelissen JJ; Schellekens JF; Kraaijeveld CA; Verhoef J
    Neth J Med; 1991 Oct; 39(3-4):170-6. PubMed ID: 1791879
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Survival in selected patients with gram-negative sepsis after adjunctive therapy with HA-1A.
    van Dissel JT; van Furth R; Compier BA; Feuth HD; Frolich M
    Lancet; 1993 Apr; 341(8850):959-60. PubMed ID: 8096292
    [No Abstract]   [Full Text] [Related]  

  • 31. Therapies for sepsis. Emerging therapies for sepsis and septic shock.
    Abraham E
    West J Med; 1997 Mar; 166(3):195-200. PubMed ID: 9143195
    [No Abstract]   [Full Text] [Related]  

  • 32. Lessons learned from clinical trials on monoclonal anti-endotoxin antibody.
    Weil MH
    Arch Intern Med; 1994 Jun; 154(11):1183. PubMed ID: 8203986
    [No Abstract]   [Full Text] [Related]  

  • 33. Update on monoclonal antibody therapy in the gram-negative sepsis syndrome.
    Hecker RB
    J Am Osteopath Assoc; 1992 Aug; 92(8):1017-20. PubMed ID: 1429060
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Observations using antiendotoxin antibody (E5) as adjuvant therapy in humans with suspected, serious, gram-negative sepsis.
    Greenberg RN; Wilson KM; Kunz AY; Wedel NI; Gorelick KJ
    Crit Care Med; 1992 Jun; 20(6):730-5. PubMed ID: 1597023
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Septomonab (Centoxin) in the treatment of gram-negative septicemia].
    Fomsgaard A
    Ugeskr Laeger; 1993 Apr; 155(14):1066-71. PubMed ID: 8497944
    [No Abstract]   [Full Text] [Related]  

  • 36. Therapies directed against endotoxin--has the time come?
    Quezado ZM; Hoffman WD
    West J Med; 1993 Apr; 158(4):424-5. PubMed ID: 8317138
    [No Abstract]   [Full Text] [Related]  

  • 37. Role of immunomodulator therapy in sepsis.
    Caplan ES
    Am J Surg; 1993 Feb; 165(2A Suppl):20S-25S. PubMed ID: 8438996
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A controlled clinical trial of E5 murine monoclonal IgM antibody to endotoxin in the treatment of gram-negative sepsis. The XOMA Sepsis Study Group.
    Greenman RL; Schein RM; Martin MA; Wenzel RP; MacIntyre NR; Emmanuel G; Chmel H; Kohler RB; McCarthy M; Plouffe J
    JAMA; 1991 Aug; 266(8):1097-102. PubMed ID: 1865542
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Novel monoclonal antiendotoxin antibody therapy: efficacy at any price?
    Fant WK
    Pharmacoeconomics; 1993 Jun; 3(6):437-45. PubMed ID: 10146878
    [No Abstract]   [Full Text] [Related]  

  • 40. Anti-lipopolysaccharide and anti-tumor necrosis factor/cachectin antibodies for the treatment of gram-negative bacteremia and septic shock.
    Calandra T; Baumgartner JD; Glauser MP
    Prog Clin Biol Res; 1991; 367():141-59. PubMed ID: 1924424
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.